Months after withdrawing its only commercial product, Ocaliva, from the market, Intercept Pharmaceuticals is letting go of 146 employees from its New Jersey campus, according to a Worker Adjustment and Retraining Notification (WARN) Act posting.
Months after withdrawing its only commercial product, Ocaliva, from the market, Intercept Pharmaceuticals is letting go of 146 employees from its New Jersey campus, according to a Worker Adjustment and Retraining Notification (WARN) Act posting.